Optimizing denileukin diftitox (Ontak®) therapy

被引：43

作者：

Duvic, Madeleine ^{[1
]}

Talpur, Rakhshandra ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Internal Med, Dept Dermatol, Houston, TX 77030 USA

来源：

FUTURE ONCOLOGY | 2008年 / 4卷 / 04期

关键词：

CD25; CTCL; fusion protein; graft-versus-host disease; IL-2; receptor; mycosis fungoides; Sezary syndrome;

D O I：

10.2217/14796694.4.4.457

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Denileukin diftitox (Ontak (R)) is a novel recombinant fusion protein consisting of peptide sequences for the enzymatically active and membrane translocation domain of diphtheria toxin linked to human IL-2. Denileukin diffitox specifically binds to IL-2 receptors on the cell membrane, is internalized via receptor-mediated endocytosis and inhibits protein synthesis by ADP ribosylation of elongation factor 2, resulting in cell death. This article focuses on the clinical trial that led to the US FDA approval of the drug for cutaneous T-cell lymphoma in 1999, and other investigational studies for hematologic malignancies, recurrent and refractory chronic lymphocytic leukemia, non-Hodgkin B-cell lymphoma, graft-versus-host disease and autoimmune disease, demonstrating the activity and adverse effects of the drug.

引用

页码：457 / 469

页数：13

共 46 条

[1] Administration of DAB389IL-2 to patients with recalcitrant psoriasis:: A double-blind, phase II multicenter trial [J].

Bagel, J ;

Garland, WT ;

Breneman, D ;

Holick, M ;

Littlejohn, TW ;

Crosby, D ;

Faust, H ;

Fivenson, D ;

Nichols, J .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (06) :938-944

[2] Regulatory T cells in ovarian cancer: Biology and therapeutic potential [J].

Barnett, B ;

Kryczek, I ;

Cheng, P ;

Zou, WP ;

Curiel, TJ .

AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2005, 54 (06) :369-377

[3] A complete and durable response to denileukin diftitox in a patient with mycosis fungoides [J].

Carretero-Margolis, CD ;

Fivenson, DP .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (02) :275-276

[4] Incidence of cutaneous T-Cell lymphoma in the United States, 1973-2002 [J].

Criscione, Vincent D. ;

Weinstock, Martin A. .

ARCHIVES OF DERMATOLOGY, 2007, 143 (07) :854-859

[5] Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma [J].

Dang, Nam H. ;

Fayad, Luis ;

McLaughlin, Peter ;

Romaguara, Jorge E. ;

Hagemeister, Fredrick ;

Goy, Andre ;

Neelapu, Sattva ;

Samaniego, Felipe ;

Walker, Pamela L. ;

Wang, Michael ;

Rodriguez, Maria A. ;

Tong, Ann T. ;

Pro, Barbara .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) :502-505

[6] Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma [J].

Dang, NH ;

Hagemeister, FB ;

Pro, B ;

McLaughlin, P ;

Romaguera, JE ;

Jones, D ;

Samuels, B ;

Samaniego, F ;

Younes, A ;

Wang, M ;

Goy, A ;

Rodriguez, MA ;

Walker, PL ;

Arredondo, Y ;

Tong, AT ;

Fayad, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) :4095-4102

[7] Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK®) [J].

Duvic, M ;

Kuzel, T ;

Olsen, EA ;

Martin, AG ;

Foss, FM ;

Kim, YH ;

Heald, PW ;

Bacha, P ;

Nichols, J ;

Liepa, A .

CLINICAL LYMPHOMA, 2002, 2 (04) :222-228

[8]

Duvic Madeleine, 2007, Oncology (Williston Park), V21, P33

[9] A phase-1 trial of bexarotene and denileukin difftitox in patients with relapsed or refractory cutaneous T-cell lymphoma [J].

Foss, F ;

Demierre, MF ;

DiVenuti, G .

BLOOD, 2005, 106 (02) :454-457

[10]

FOSS F, 2006, BLOOD, V108, P2712

← 1 2 3 4 5 →